Psoriasis

(Note: For PDF File Swipe To The End Of Article)

Definition of Psoriasis

Psoriasis is a chronic, immune-mediated inflammatory skin disorder characterized by excessive proliferation and abnormal differentiation of keratinocytes, resulting in thick, scaly, erythematous plaques on the skin. It is one of the most common chronic dermatological conditions worldwide and affects individuals of all ages, although it most commonly begins during early adulthood or middle age.

Unlike infectious skin diseases, psoriasis is not contagious and cannot spread from one person to another through physical contact, sharing clothes, or using common household items. The disease develops because of a complex interaction between genetic predisposition, immune system dysregulation, and environmental triggers that initiate and sustain chronic inflammation within the skin.

In healthy skin, keratinocytes require approximately 28 to 30 days to mature and migrate from the basal layer of the epidermis to the surface where they are eventually shed. In psoriasis, this process accelerates dramatically and may occur within only three to five days. Because the body cannot shed these cells rapidly enough, they accumulate on the skin surface and form the characteristic thick, silvery scales associated with the disease.

Psoriasis is now recognized as a systemic inflammatory disease rather than merely a skin disorder. Chronic inflammation associated with psoriasis can affect multiple organs and body systems, increasing the risk of cardiovascular disease, metabolic syndrome, obesity, diabetes mellitus, and inflammatory arthritis.

---

Epidemiology

Psoriasis affects approximately 2–3% of the world's population, making it one of the most prevalent chronic inflammatory skin disorders. However, prevalence varies considerably among different ethnic groups and geographic regions.

The disease is more common in populations living in northern Europe and North America, whereas lower rates are reported in East Asian and African populations. Environmental factors such as climate, sunlight exposure, and genetic background contribute to these variations.

Psoriasis can develop at any age, from infancy to old age, but two distinct peaks of onset are commonly observed. The first peak occurs between the ages of 15 and 35 years and is often associated with a stronger family history and genetic predisposition. The second peak typically occurs between the ages of 50 and 60 years.

Both males and females are affected equally, although certain forms of psoriasis may show slight gender predominance in some studies. Childhood psoriasis accounts for a significant proportion of cases and often presents differently from adult disease, with lesions frequently affecting the face and flexural areas.

Family history is an important epidemiological feature. Approximately one-third of patients have at least one first-degree relative with psoriasis, and the risk increases substantially when both parents are affected.

---

Etiology and Risk Factors

The exact cause of psoriasis remains incompletely understood, but it is generally accepted that the disease results from interactions between genetic susceptibility and environmental triggers that activate abnormal immune responses.

Genetic predisposition plays a central role in disease development. Numerous susceptibility genes have been identified, particularly those involved in immune regulation and antigen presentation. Individuals carrying these genes are more likely to develop psoriasis after exposure to triggering factors.

Several environmental factors can precipitate the onset of psoriasis or worsen existing disease:

Infections

Bacterial and viral infections are well-known triggers. Streptococcal throat infections are strongly associated with guttate psoriasis, especially in children and young adults. HIV infection may also worsen psoriasis severity due to immune dysregulation.

Trauma to the Skin

Physical injury such as cuts, burns, surgical scars, insect bites, tattoos, or abrasions may lead to the development of psoriatic lesions at the site of injury, a phenomenon known as the Koebner phenomenon.

Medications

Certain drugs are capable of inducing psoriasis or causing exacerbations. Common examples include:

• Beta-blockers
• Lithium
• Antimalarial drugs
• Interferons
• Nonsteroidal anti-inflammatory drugs
• Withdrawal of systemic corticosteroids

Psychological Stress

Stress is one of the most frequently reported triggers. Emotional stress activates inflammatory pathways and can precipitate new lesions or worsen existing disease activity.

Smoking and Alcohol Consumption

Smoking increases the risk of developing psoriasis and is particularly associated with palmoplantar pustular psoriasis. Excessive alcohol intake may worsen disease severity and reduce treatment effectiveness.

Obesity

Obesity contributes to chronic systemic inflammation and is strongly linked to more severe disease. Adipose tissue produces inflammatory cytokines that can aggravate psoriatic inflammation.

Climate

Cold weather often worsens psoriasis because low humidity leads to dry skin and reduced exposure to ultraviolet radiation. Many patients report improvement during sunny summer months.

---

Genetic Basis of Psoriasis

Psoriasis is one of the most strongly genetically linked dermatological disorders. Multiple genes have been implicated, confirming the polygenic nature of the disease.

The strongest association exists with the PSORS1 locus located on chromosome 6 within the major histocompatibility complex region. Within this locus, the HLA-Cw6 allele is considered the most important genetic marker for early-onset psoriasis.

Individuals carrying HLA-Cw6 frequently develop disease at younger ages and often exhibit guttate psoriasis following streptococcal infections.

Additional genes associated with psoriasis include those involved in:

• T-cell activation
• Cytokine signaling
• Interleukin pathways
• Nuclear factor-kappa B regulation
• Skin barrier integrity

Mutations affecting interleukin-23 and interleukin-17 pathways are particularly important because these cytokines are central mediators of psoriatic inflammation and have become major therapeutic targets in modern biologic therapy.

Twin studies provide strong evidence for genetic influence. Monozygotic twins show significantly higher concordance rates compared with dizygotic twins, although environmental factors remain necessary for disease expression.

---

Pathophysiology

The pathogenesis of psoriasis involves a highly complex interaction between dendritic cells, T lymphocytes, keratinocytes, and inflammatory cytokines.

The process begins when environmental triggers activate dendritic cells within genetically susceptible individuals. These dendritic cells release inflammatory mediators and present antigens to naïve T lymphocytes in regional lymph nodes.

Activated T cells migrate back to the skin where they release numerous cytokines, including:

• Tumor necrosis factor-alpha (TNF-α)
• Interleukin-17
• Interleukin-23
• Interleukin-22
• Interleukin-12

These cytokines stimulate keratinocyte proliferation and inhibit normal cell maturation, leading to excessive epidermal growth.

The epidermis becomes markedly thickened, a process known as acanthosis. Simultaneously, inflammatory cells infiltrate both the epidermis and dermis, causing redness, swelling, and increased vascularity.

New blood vessels form within the dermis through angiogenesis, explaining the characteristic erythematous appearance of psoriatic plaques and the pinpoint bleeding seen when scales are removed, known as the Auspitz sign.

This inflammatory cycle becomes self-perpetuating, leading to chronic disease activity with periods of remission and exacerbation.

---

Types of Psoriasis

Psoriasis exists in several clinical forms, each with distinct characteristics and patterns of involvement.

Plaque Psoriasis

Plaque psoriasis, also known as psoriasis vulgaris, accounts for approximately 80–90% of cases. It presents with sharply demarcated, raised, erythematous plaques covered by thick silvery-white scales.

Common sites include:

• Elbows
• Knees
• Scalp
• Lower back
• Extensor surfaces of limbs

The lesions are often symmetrical and may vary considerably in size.

Guttate Psoriasis

Guttate psoriasis presents with numerous small, drop-like lesions scattered over the trunk and proximal limbs. It commonly follows streptococcal throat infections and primarily affects children and young adults.

Many patients experience complete resolution, although some eventually progress to chronic plaque psoriasis.

Inverse Psoriasis

Inverse psoriasis affects flexural areas such as:

• Axillae
• Groin
• Inframammary folds
• Intergluteal cleft

Because of moisture and friction in these areas, lesions appear smooth, shiny, and red rather than scaly.

Pustular Psoriasis

Pustular psoriasis is characterized by sterile pustules filled with neutrophils. It may be localized or generalized and can occasionally become life-threatening when extensive skin involvement occurs.

Generalized pustular psoriasis often presents with fever, malaise, and systemic toxicity.

Erythrodermic Psoriasis

Erythrodermic psoriasis is a severe form involving widespread redness and scaling affecting more than 90% of body surface area.

Patients may develop:

• Hypothermia
• Dehydration
• Electrolyte imbalance
• High-output cardiac failure
• Secondary infections

This condition represents a dermatological emergency requiring hospitalization.

Nail Psoriasis

Nail involvement occurs in a substantial proportion of patients and may affect fingernails, toenails, or both.

Typical findings include:

• Nail pitting
• Onycholysis
• Subungual hyperkeratosis
• Oil-drop discoloration
• Nail plate thickening

Nail disease strongly correlates with the future development of psoriatic arthritis.

---

Clinical Features

The hallmark lesion of psoriasis is a well-defined erythematous plaque covered by thick silvery scales. The lesions may vary from a few isolated patches to widespread body involvement.

Pruritus is common and may significantly impair quality of life. Some patients report burning, soreness, or pain, particularly when lesions occur in flexural areas or on the palms and soles.

The scalp is one of the most frequently affected sites and may show diffuse scaling resembling severe dandruff. Hair loss is uncommon and usually reversible.

Palmoplantar involvement can interfere with walking, writing, and manual work due to painful fissures and thickened skin.

Characteristic clinical signs include:

• Auspitz sign
• Koebner phenomenon
• Candle grease sign
• Woronoff ring

Disease severity fluctuates over time, with periods of remission alternating with episodes of worsening triggered by infections, stress, medications, or environmental factors.

The psychosocial impact of visible skin lesions may be profound, leading to embarrassment, social withdrawal, anxiety, depression, and reduced quality of life comparable to many chronic systemic illnesses.

Triggering Factors

Although psoriasis has a strong genetic basis, environmental and lifestyle factors often determine when the disease first appears and how severe it becomes over time. Many patients can identify specific triggers that precede flare-ups, and recognition of these factors is an important part of long-term disease management.

Psychological stress is among the most frequently reported triggers. Emotional stress activates the hypothalamic-pituitary-adrenal axis and stimulates the release of inflammatory mediators that can worsen skin inflammation. Major life events such as examinations, bereavement, financial difficulties, relationship problems, and occupational stress frequently precede disease exacerbations.

Upper respiratory tract infections are particularly important in guttate psoriasis. Streptococcal pharyngitis can trigger widespread eruptions of small psoriatic lesions, especially in children and adolescents. Viral infections may also precipitate disease flares in susceptible individuals.

Skin injury can induce new lesions through the Koebner phenomenon. Trauma such as cuts, surgical incisions, burns, tattoos, vaccinations, insect bites, and excessive scratching may all produce psoriatic plaques at the affected sites. Lesions usually appear within one to three weeks after injury.

Certain medications are recognized causes of psoriasis exacerbation. These include:

• Lithium used for bipolar disorder.
• Beta-blockers used in hypertension and cardiovascular disease.
• Antimalarial drugs such as chloroquine and hydroxychloroquine.
• Interferons used in viral hepatitis and malignancy treatment.
• Some nonsteroidal anti-inflammatory drugs.
• Rapid withdrawal of systemic corticosteroids.

Smoking contributes significantly to disease severity and treatment resistance. Tobacco smoke promotes oxidative stress and enhances inflammatory cytokine production, worsening skin lesions and increasing the risk of pustular psoriasis.

Excessive alcohol consumption is another recognized trigger. Alcohol stimulates inflammatory pathways and interferes with treatment adherence and effectiveness.

Obesity plays a dual role as both a trigger and a consequence of severe disease. Adipose tissue actively secretes inflammatory cytokines such as TNF-alpha and interleukin-6, creating a pro-inflammatory state that worsens psoriasis.

Cold and dry climates frequently aggravate symptoms because reduced humidity leads to skin dryness and increased scaling. In contrast, moderate sunlight exposure often improves lesions because ultraviolet radiation suppresses cutaneous immune responses.

Hormonal changes during puberty, pregnancy, and menopause may influence disease activity, although responses vary among individuals.

---

Diagnosis

The diagnosis of psoriasis is primarily clinical and is usually based on the appearance and distribution of skin lesions. In many patients, an experienced clinician can establish the diagnosis without laboratory investigations.

A detailed medical history is essential and should include:

• Age of onset.
• Family history of psoriasis.
• Previous episodes of skin disease.
• Recent infections.
• Medication history.
• Presence of joint symptoms.
• Occupational exposures.
• Smoking and alcohol habits.

Physical examination focuses on lesion morphology, distribution, and severity. Typical plaques are sharply demarcated, erythematous, and covered by thick silvery scales.

Several classical physical signs support the diagnosis.

Auspitz Sign

When scales are gently removed from a psoriatic plaque, tiny pinpoint areas of bleeding may appear due to exposure of dilated capillaries within the dermal papillae. This phenomenon is known as the Auspitz sign.

Candle Grease Sign

Gentle scraping of the lesion may produce fine scales resembling candle wax shavings, referred to as the candle grease sign.

Koebner Phenomenon

Development of new lesions at sites of trauma strongly supports the diagnosis of psoriasis.

Woronoff Ring

Some lesions demonstrate a pale ring surrounding the plaque during periods of spontaneous improvement or treatment response.

Skin biopsy is rarely necessary but may be useful in atypical cases or when differentiation from other inflammatory dermatoses is difficult.

Histopathological features include:

• Hyperkeratosis.
• Parakeratosis.
• Acanthosis.
• Elongation of rete ridges.
• Dilated dermal capillaries.
• Munro microabscesses.
• Spongiform pustules of Kogoj.

Laboratory investigations are generally normal in uncomplicated psoriasis but may be useful for assessing associated conditions or treatment suitability.

---

Differential Diagnosis

Several dermatological conditions may resemble psoriasis and should be considered during clinical evaluation.

Seborrheic Dermatitis

Seborrheic dermatitis commonly affects the scalp, face, and chest. Lesions tend to be greasy and yellowish rather than thick and silvery. The condition often involves areas rich in sebaceous glands.

Eczema

Eczema typically presents with poorly defined borders, intense itching, and exudative lesions during acute phases. Chronic eczema may become lichenified and resemble psoriasis, particularly on the hands.

Tinea Corporis

Dermatophyte infections can mimic plaque psoriasis, especially when lesions are annular and scaly. Fungal microscopy and culture may be required for differentiation.

Pityriasis Rosea

This condition often begins with a herald patch followed by multiple smaller lesions distributed along skin cleavage lines. The disease is usually self-limiting.

Lichen Planus

Lichen planus produces violaceous, polygonal, pruritic papules that may occasionally resemble guttate psoriasis.

Cutaneous T-Cell Lymphoma

Early mycosis fungoides may mimic chronic plaque psoriasis and occasionally requires repeated biopsies for diagnosis.

Secondary Syphilis

Generalized papulosquamous eruptions involving the palms and soles should raise suspicion for secondary syphilis.

---

Severity Assessment

Assessment of disease severity is important because treatment selection depends largely on the extent and impact of disease activity.

Severity is determined not only by the amount of skin involved but also by lesion location, symptoms, and effects on quality of life.

Body Surface Area Assessment

Body surface area estimates the percentage of skin affected.

• Mild psoriasis involves less than 3% of body surface area.
• Moderate psoriasis involves 3–10%.
• Severe psoriasis affects more than 10%.

The patient's palm including fingers approximately represents 1% of total body surface area and is commonly used for estimation.

Psoriasis Area and Severity Index

The Psoriasis Area and Severity Index, commonly called PASI, is widely used in clinical trials and specialist practice.

The score evaluates:

• Redness.
• Thickness.
• Scaling.
• Extent of involvement.

Scores range from 0 to 72, with higher scores indicating more severe disease.

Dermatology Life Quality Index

Quality of life assessment is increasingly recognized as an essential component of severity evaluation.

Patients may experience:

• Sleep disturbances.
• Reduced work productivity.
• Social embarrassment.
• Sexual difficulties.
• Anxiety and depression.

Even limited disease affecting the face, scalp, hands, feet, or genital region may have profound psychosocial consequences despite low body surface area involvement.

---

Complications of Psoriasis

Psoriasis is now regarded as a systemic inflammatory disorder associated with numerous complications beyond the skin.

Psoriatic Arthritis

Psoriatic arthritis develops in approximately 20 to 30 percent of patients with psoriasis. Joint disease may occur before, after, or simultaneously with skin lesions.

Clinical manifestations include:

• Joint pain.
• Morning stiffness.
• Swelling.
• Reduced range of motion.
• Enthesitis.
• Dactylitis.

Failure to recognize and treat psoriatic arthritis can lead to irreversible joint destruction and disability.

Cardiovascular Disease

Chronic systemic inflammation contributes to accelerated atherosclerosis and endothelial dysfunction.

Patients with severe psoriasis have increased risks of:

• Hypertension.
• Coronary artery disease.
• Myocardial infarction.
• Stroke.
• Peripheral vascular disease.

Metabolic Syndrome

Psoriasis is strongly associated with obesity, insulin resistance, dyslipidemia, and hypertension.

The inflammatory cytokines involved in psoriasis overlap significantly with those involved in metabolic syndrome.

Diabetes Mellitus

Insulin resistance is more common among patients with moderate to severe disease, increasing the risk of type 2 diabetes mellitus.

Non-Alcoholic Fatty Liver Disease

Hepatic steatosis occurs more frequently in patients with psoriasis, particularly among those with obesity and metabolic syndrome.

Inflammatory Bowel Disease

Crohn disease and ulcerative colitis share several inflammatory pathways with psoriasis and occur more commonly in affected individuals.

Depression and Anxiety

Visible skin lesions may profoundly affect self-esteem and social functioning.

Patients frequently experience:

• Depression.
• Anxiety disorders.
• Social isolation.
• Reduced self-confidence.
• Suicidal ideation in severe cases.

Psychological complications deserve the same attention as physical manifestations of disease.

Ocular Complications

Some patients develop inflammatory eye diseases including:

• Conjunctivitis.
• Blepharitis.
• Episcleritis.
• Uveitis.

Early recognition is important to prevent visual impairment.

Chronic Kidney Disease

Persistent systemic inflammation may contribute to renal dysfunction, particularly in severe long-standing disease or patients receiving nephrotoxic medications.

Management and Treatment

The management of psoriasis aims to control inflammation, reduce symptoms, improve quality of life, prevent complications, and maintain long-term remission. Since psoriasis is a chronic disease with periods of exacerbation and remission, treatment is usually individualized according to disease severity, lesion distribution, patient preference, associated comorbidities, and response to previous therapies.

Treatment selection depends upon several factors including:

• Extent of skin involvement.
• Presence of psoriatic arthritis.
• Nail involvement.
• Patient age.
• Pregnancy status.
• Presence of metabolic syndrome or cardiovascular disease.
• Previous treatment history.
• Impact on quality of life.

Mild disease is generally managed with topical therapy, whereas moderate to severe psoriasis often requires phototherapy, systemic medications, or biologic agents.

The treatment goals include:

• Reduction of erythema and scaling.
• Relief of itching and discomfort.
• Prevention of relapses.
• Improvement in social and psychological wellbeing.
• Prevention of joint damage in psoriatic arthritis.
• Reduction of systemic inflammatory burden.

---

Topical Therapy

Topical treatment remains the cornerstone of management for mild and localized psoriasis and is frequently combined with systemic therapies in severe disease.

Topical Corticosteroids

Topical corticosteroids are among the most commonly prescribed medications for psoriasis. They suppress inflammatory cytokine production, reduce keratinocyte proliferation, and decrease redness and itching.

Different strengths are selected depending upon lesion location:

• Mild potency steroids for the face and flexures.
• Moderate potency steroids for the trunk.
• High potency steroids for palms, soles, and thick plaques.

Long-term use may cause:

• Skin atrophy.
• Striae formation.
• Telangiectasia.
• Tachyphylaxis.
• Rebound flares after sudden discontinuation.

Intermittent use and gradual tapering help minimize complications.

Vitamin D Analogues

Calcipotriol and calcitriol regulate keratinocyte proliferation and differentiation.

These agents are particularly useful for chronic plaque psoriasis and may be combined with topical corticosteroids for improved efficacy.

Advantages include:

• Good long-term safety profile.
• Reduced risk of skin atrophy.
• Effective maintenance therapy.

Local irritation may occur, especially on sensitive skin areas.

Coal Tar Preparations

Coal tar has been used for more than a century in psoriasis treatment.

Its actions include:

• Anti-inflammatory effects.
• Reduction of scaling.
• Suppression of epidermal proliferation.

Limitations include unpleasant odor, staining of clothes, and cosmetic acceptability.

Salicylic Acid

Salicylic acid acts as a keratolytic agent by softening and removing scales.

Removal of scales improves penetration of other topical medications and enhances treatment effectiveness.

Topical Calcineurin Inhibitors

Tacrolimus and pimecrolimus are particularly useful in sensitive areas such as:

• Face.
• Eyelids.
• Axillae.
• Groin.
• Genital region.

These medications avoid steroid-induced skin thinning and may be used for prolonged periods.

Anthralin

Anthralin slows keratinocyte proliferation and reduces inflammation.

Despite its effectiveness, its use is limited because of skin irritation and staining of skin and clothing.

---

Phototherapy

Ultraviolet light therapy is an effective treatment option for moderate psoriasis and for patients who fail to respond adequately to topical medications.

Ultraviolet radiation suppresses abnormal immune activation within the skin and decreases keratinocyte proliferation.

Narrowband UVB Therapy

Narrowband ultraviolet B is currently the most widely used form of phototherapy.

Treatment is usually administered two to three times weekly for several months.

Benefits include:

• Improvement in plaque thickness.
• Reduction of scaling.
• Long remission periods.
• Good safety profile.

Broadband UVB Therapy

Broadband UVB was commonly used before the introduction of narrowband UVB and is now less frequently utilized.

PUVA Therapy

PUVA therapy combines psoralen administration with ultraviolet A exposure.

Psoralen increases skin sensitivity to ultraviolet radiation and enhances therapeutic effectiveness.

PUVA is particularly useful in:

• Severe plaque psoriasis.
• Palmoplantar psoriasis.
• Pustular psoriasis.

Potential adverse effects include:

• Nausea.
• Photosensitivity reactions.
• Cataract formation without eye protection.
• Increased long-term risk of skin malignancy.

---

Systemic Therapy

Patients with extensive disease often require systemic medications capable of suppressing the underlying immune abnormalities responsible for psoriasis.

Methotrexate

Methotrexate remains one of the most widely used systemic treatments for moderate to severe psoriasis.

It inhibits DNA synthesis and suppresses rapidly proliferating inflammatory cells.

Benefits include:

• Improvement of skin lesions.
• Treatment of psoriatic arthritis.
• Long clinical experience.

Potential adverse effects include:

• Hepatotoxicity.
• Bone marrow suppression.
• Pulmonary toxicity.
• Gastrointestinal symptoms.

Regular monitoring of liver function and blood counts is essential.

Cyclosporine

Cyclosporine suppresses T-cell activation and produces rapid improvement in severe psoriasis.

It is particularly useful in:

• Erythrodermic psoriasis.
• Generalized pustular psoriasis.
• Severe acute flares.

Long-term use is limited by:

• Hypertension.
• Nephrotoxicity.
• Increased infection risk.

Acitretin

Acitretin is an oral retinoid that normalizes keratinocyte differentiation.

It is especially effective in:

• Pustular psoriasis.
• Palmoplantar psoriasis.
• Hyperkeratotic lesions.

Common adverse effects include:

• Dry lips.
• Dry eyes.
• Hair thinning.
• Elevated lipid levels.

Acitretin is highly teratogenic and pregnancy must be avoided during treatment and for several years afterward.

Apremilast

Apremilast inhibits phosphodiesterase-4 and reduces inflammatory cytokine production.

Advantages include:

• Oral administration.
• No requirement for extensive laboratory monitoring.
• Good safety profile.

Common side effects include:

• Nausea.
• Diarrhea.
• Weight loss.
• Headache.

---

Biologic Therapy

The development of biologic therapy has revolutionized psoriasis treatment by specifically targeting inflammatory pathways involved in disease pathogenesis.

Biologic agents are generally reserved for moderate to severe disease that fails to respond to conventional systemic therapy.

Tumor Necrosis Factor-Alpha Inhibitors

Examples include:

• Infliximab.
• Adalimumab.
• Etanercept.

These medications block TNF-alpha, a key inflammatory cytokine involved in psoriasis.

They are highly effective for both skin lesions and psoriatic arthritis.

Interleukin-12 and Interleukin-23 Inhibitors

Ustekinumab targets interleukin-12 and interleukin-23 pathways and provides long-lasting disease control with relatively infrequent injections.

Interleukin-17 Inhibitors

Examples include:

• Secukinumab.
• Ixekizumab.
• Brodalumab.

These medications often produce rapid and dramatic improvement in severe plaque psoriasis.

Interleukin-23 Inhibitors

Examples include:

• Guselkumab.
• Risankizumab.
• Tildrakizumab.

These agents offer excellent long-term disease control with convenient dosing schedules.

Potential risks associated with biologic therapy include:

• Serious infections.
• Reactivation of latent tuberculosis.
• Opportunistic infections.
• Injection site reactions.

Appropriate screening before treatment initiation is essential.

---

Psoriatic Arthritis Management

Early diagnosis and aggressive treatment of psoriatic arthritis are necessary to prevent irreversible joint damage.

Management commonly includes:

• Nonsteroidal anti-inflammatory drugs.
• Methotrexate.
• Biologic therapy.
• Physiotherapy.
• Occupational therapy.

Regular assessment of joint symptoms should be performed in all psoriasis patients regardless of skin severity.

---

Management of Nail Psoriasis

Nail psoriasis is often difficult to treat because medications penetrate the nail plate poorly.

Treatment options include:

• Topical corticosteroids.
• Intralesional steroid injections.
• Systemic therapy.
• Biologic medications.

Improvement may require many months because of slow nail growth.

---

Management During Pregnancy

Pregnancy influences psoriasis unpredictably.

Some women experience improvement, whereas others develop worsening disease activity.

Preferred treatment options during pregnancy include:

• Emollients.
• Low potency topical corticosteroids.
• Selected phototherapy regimens.

Methotrexate and acitretin are contraindicated because of severe teratogenic effects.

---

Patient Education and Lifestyle Modifications

Patient education is one of the most important components of psoriasis management.

Patients should understand that psoriasis is a chronic inflammatory disease rather than an infection and that treatment aims for control rather than permanent cure.

Adherence to therapy significantly improves long-term outcomes.

Recommended lifestyle modifications include:

• Maintaining ideal body weight.
• Smoking cessation.
• Avoiding excessive alcohol consumption.
• Regular physical activity.
• Stress reduction techniques.
• Adequate sleep.
• Proper skin hydration.

Daily use of moisturizers reduces scaling, itching, and skin cracking while improving barrier function.

Patients should avoid:

• Excessive scratching.
• Harsh soaps.
• Skin trauma.
• Abrupt discontinuation of treatment.

Moderate sunlight exposure may improve symptoms in some individuals, although excessive exposure increases the risk of skin cancer and sunburn.

Psychological support may be beneficial for patients experiencing depression, anxiety, or social isolation due to visible skin lesions.

Support groups and counseling services can improve coping strategies and treatment adherence.

---

Prognosis and Follow-Up

Psoriasis is generally a lifelong condition characterized by alternating periods of remission and relapse.

The clinical course varies considerably between individuals.

Some patients experience mild intermittent disease with prolonged remission periods, whereas others develop persistent severe inflammation requiring continuous treatment.

Factors associated with more severe disease include:

• Early age of onset.
• Strong family history.
• Nail involvement.
• Obesity.
• Smoking.
• Presence of psoriatic arthritis.

Regular follow-up is important for:

• Monitoring treatment effectiveness.
• Detecting medication toxicity.
• Identifying cardiovascular risk factors.
• Screening for psoriatic arthritis.
• Assessing quality of life.

Patients receiving systemic therapy require periodic laboratory investigations including:

• Complete blood count.
• Liver function tests.
• Renal function tests.
• Lipid profile where appropriate.

Early recognition and management of associated comorbidities significantly improve long-term outcomes and reduce overall disease burden.